For research use only
| Cat No. | ABC-X0283C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human NRAS (G12D_Y96D) BAF3 Cell Line serves as a model for understanding NRAS mutation-driven signaling alterations in hematologic cancers.
Human NRAS (G12D_Y96D) BAF3 Cell Line is a genetically engineered model derived from murine Ba/F3 cells via stable integration of human NRAS gene with G12D and Y96D point mutations. Lentiviral delivery ensures sustained expression, and edited cells are expanded at low passage (<P20). Validation is performed at gene level using qRT-PCR. Target NRAS mutations at G12D are frequently observed in acute myeloid leukemia and melanoma, promoting constitutive MAPK activation. The additional Y96D mutation modulates effector binding and downstream signaling. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0283C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This dual-mutant NRAS BAF3 line supports research on NRAS-driven transformation, therapeutic resistance pathways, and screening of selective inhibitors in hematological and skin cancers.